ReEmerge says it raised $37M to test a brain implant for chronic TBI

Why it matters

ReEmerge is putting $37 million behind the leap from a five-patient academic result to a multicenter test. Success would open a restorative treatment path for chronic TBI; the current evidence remains preliminary and invasive.

Nicholas Schiff and Jaimie Henderson are taking ReEmerge out of stealth with a company-reported $37 million Series A and a plan to test whether deep brain stimulation can restore cognitive function years after a traumatic brain injury.

ReEmerge said in its September 15th launch announcement that U.S. Venture Partners and Sante Ventures co-led the oversubscribed round. Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group and Dendrion Ventures also participated. ReEmerge did not attach a valuation to the financing.

The Edina, Minnesota, medtech will use the money to advance Cognitive Network Restoration Therapy, or CNRT, an investigational implant that stimulates networks in the central thalamus. ReEmerge's thesis is that some circuits disrupted by brain injury remain alive but underactive, leaving room for carefully placed electrical stimulation to improve attention, processing speed and executive function.

Schiff has spent decades building the scientific argument behind that thesis. The Weill Cornell Medicine neurologist directs the Laboratory of Cognitive Neuromodulation and studies impaired consciousness, arousal and electrical stimulation of the brain. Schiff and colleagues led a 2007 Nature paper that reported bilateral deep-brain stimulation of the central thalamus in a patient who had remained in a minimally conscious state for six years after traumatic brain injury. Weill Cornell credits him with more than 100 publications and 12 patents.

Henderson, a Stanford professor of neurosurgery, directs the university's stereotactic and functional neurosurgery program. Recent academic disclosures identify Schiff and Henderson as co-founders and shareholders of Re-EmergeDBS, the name used for ReEmerge in research publications.

"It has been very rewarding to see the arc of benchtop science moving forward," Schiff said in the launch announcement. The Series A finances the harder part of that arc: showing that an effect observed in a tiny academic study can survive a larger, multicenter clinical program.

From five patients to a 40-patient study

ReEmerge's starting evidence comes from a phase 1 feasibility study published in Nature Medicine. The prior human evidence centers on five patients with chronic moderate-to-severe TBI who completed the treatment phase.

The study's participant data show that those five patients had sustained their injuries years earlier. All five improved on the primary measure, Trail Making Test Part B, which assesses skills including attention, task switching and information-processing speed.

Those results established an early human signal, not a commercial therapy. Five completed cases cannot resolve how much benefit the treatment produces across a varied TBI population, which patients are most likely to respond or how the risks compare with the gains. The implantation procedure also leaves safety and implementation questions for a larger trial.

ReEmerge's planned CNRT study is designed as a prospective, single-arm, multicenter trial enrolling up to 40 people with chronic moderate-to-severe TBI. ReEmerge says the study will examine cognitive and functional outcomes. A single-arm design can expand the safety and performance dataset, although it will leave randomized efficacy testing for a later stage.

A follow-up paper reported autobiographical-memory improvements among participants who completed the earlier trial. Its authors cautioned that the sample was small and that differences among injuries, baseline abilities and daily fatigue could affect the results.

ReEmerge's restoration bet

Chronic TBI care commonly uses rehabilitation, structured routines and adaptive strategies to help people work around lasting cognitive deficits. ReEmerge is making a different clinical bet: targeted stimulation of the central lateral thalamus can increase activity across surviving networks and recover some lost function.

That focus separates ReEmerge from neurotechnology companies pursuing other parts of post-injury cognition. Nia Therapeutics, for example, is developing closed-loop stimulation intended to improve memory after TBI. ReEmerge is targeting a thalamic hub connected to broader attention, arousal and executive-function networks.

The platform language in ReEmerge's announcement points to eventual use in other causes of chronic cognitive impairment. The financing has a narrower job first. ReEmerge must turn a promising five-patient result into reproducible clinical evidence, establish a workable implantation and programming process across multiple centers, and define a patient population that can support later controlled studies.

The clinical-operations handoff

ReEmerge chief executive Todd Langevin will oversee the company's move from academic research into clinical development and medical-device operations.

ReEmerge is built around academic work from Weill Cornell, Stanford and the University of Utah, with foundational intellectual property licensed from Cornell. Schiff and Henderson supplied the scientific program. Langevin now has to convert it into a repeatable medical-device operation spanning manufacturing, clinical sites, regulatory work and long-term patient support.

The investor group reflects that execution risk. USVP and Sante describe early-stage healthcare investing among their areas of focus. 415 Capital focuses on medical technology, while Oxford Science Enterprises builds companies from university research. Their $37 million wager gives ReEmerge enough capital to move beyond a laboratory proof point. The upcoming study will determine whether central-thalamic stimulation can become a credible treatment program for people whose recovery has plateaued years after injury.